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ABSTRACT 
 
Background and objective: Bacterial infection is one of the most important causes of acute 
exacerbation of respiratory failure in patients with chronic obstructive pulmonary disease 
(COPD). There were few studies evaluating the effects of early intervention by antibiotic on 
respiratory bacterial infection in COPD subjects. We investigated the effect of early interven-
tion by respiratory quinolone antibiotic on the systemic inflammatory responses induced by 
streptococcal pneumonia using a mouse model of experimental emphysema.   
Methods: Experimental pulmonary emphysema was developed by a single intratracheal instil-
lation of porcine pancreatic elastase in ICR mice. Three weeks later, lethal doses of Strepto-
coccus pneumoniae were intratracheally inoculated, followed by oral administration of 
50 mg/kg body weight of Grepafloxacin (GPFX) every day from a day after tracheal inocula-
tion. 
Results: While all emphysematous mice without GPFX treatment died within 8 days, all em-
physematous mice with GPFX treatment survived. Seventy two hrs after infection, serum lev-
els of tumor necrosis factor alpha, chemokine (C-X-C motif) ligand 1, and CXCL2 (Macro-
phage inflammatory protein-2) in emphysematous mice with antibiotic therapy were signifi-
cantly lower than those without therapy.   
Conclusions: Thus, the early intervention using a respiratory quinolone antibiotic prevents 
emphysematous mice with pneumonia from severe systemic inflammation, and rescues these 
mice from death. These results suggest that early intervention using a respiratory quinolone 
may improve the outcome of the exacerbated COPD patients. 
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INTRODUCTION 
 
Chronic obstructive pulmonary disease 
(COPD) is a common disease, physiologi-
cally characterized by various levels of air-
flow obstruction, and pathologically by 
findings of pulmonary emphysema (Rabe et 
al., 2007). The prevalence of COPD in the 
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Japanese male population (40 years or 
greater) was reported to be at least 8.6 % in 
the Nippon COPD Epidemiology Study 
(Fukuchi et al., 2004). COPD is a major, 
global medical problem. The natural history 
of COPD is associated with frequent respi-
ratory tract infections, resulting in exacer-
bation, severe respiratory failure, and death 
(Rabe et al., 2007; Connors et al., 1996; 
Hurd, 2000; Schumaker and Epstein, 2004). 
However, little is known about why patients 
with COPD are susceptible to bacterial in-
fections. 
In our previous study, we have demon-
strated abnormal inflammatory process 
from lung to whole body in emphysematous 
mice with streptococcal pneumonia (Inoue 
et al., 2003; Tokairin et al., 2008). All of 
mice with pulmonary emphysema died after 
streptococcal infection within several days. 
Six hours after inoculation, the levels of 
tumor necrosis factor alpha (TNF-α), inter-
leukin-1β and -6 in bronchial alveolar lav-
age fluid (BALF) were significantly ele-
vated compared to those of control mice. 
Twenty-four hours after inoculation, the 
levels of TNF-α, chemokine (C-X-C motif) 
ligand 1 (CXCL1), and CXCL2 in bron-
chial alveolar lavage fluid (BALF) of em-
physematous mice are significantly lower 
than those of control mice. On the other 
hand, 72 hours after inoculation, the serum 
levels of TNF-α, CXCL1, and CXCL2 in 
emphysematous mice are significantly ele-
vated with systemic spread of bacteria 
compared to those in control mice. These 
findings suggest that deteriorated inflamma-
tory procedures in respiratory-infected em-
physematous mice result in severe systemic 
cytokine storm by bacteremia. Thus, it is 
speculated that early intervention by antibi-
otic may improve the outcome of COPD 
subjects with respiratory infection by pre-
venting them from the spread of bacteria 
into whole body.  
In the case of respiratory bacterial infec-
tion in patients with COPD, we have to 
consider these deteriorated inflammatory 
responses, which make the management of 
acute exacerbation of COPD difficult. Even 
though some studies reported that antibiotic 
therapies were effective for the acute exac-
erbation of COPD (Schumaker and Epstein, 
2004;Wilkinson et al., 2004), few studies 
are available which show the effect of early 
intervention by antibiotic on the systemic 
inflammatory responses induced by respira-
tory infection using a mouse model of ex-
perimental emphysema. 
Streptococcus (S.) pneumoniae is known 
to be one of the most virulent gram-positive 
bacteria in community acquired pneumonia 
in healthy and diseased individuals (Almi-
rall et al., 2007). S. pneumoniae is a fre-
quently encountered pathogen in respiratory 
infections, and causes acute exacerbation in 
patients with COPD (Schumaker and Ep-
stein, 2004; Lode et al., 2007; Soler et al., 
1998; Miravitlles et al., 1999). Therefore, 
the prevention of pneumococcal infections 
in COPD patients is at the core of their 
management. 
Grepafloxacin (GPFX) is a broad-
spectrum fluoroquinolone with superior 
activity against gram-positive bacteria such 
as S. pneumoniae compared with older qui-
nolones, and is classified into the respira-
tory quinolone (Norrby, 1997). The respira-
tory quinolones are expected to bring the 
good outcome for the treatments of respira-
tory infection including S. pneumoniae 
(Cook et al., 1995; Wakebe et al., 1994). 
Indeed, many reports have shown their ef-
fectiveness in clinic (DeAbate et al., 1999; 
Reinert et al., 2005; Suzuki et al., 2005). 
However, the effects of respiratory qui-
nolones on survivals and systemic inflam-
matory responses in infected COPD animal 
models have not been demonstrated. 
In these backgrounds, we evaluated the 
usefulness of early intervention by a respi-
ratory quinolone against the streptococcal 
infection in emphysematous mice. We 
demonstrated early intervention against 
streptococcal pneumonia using GPFX 
greatly improved the survival and inflam-
matory responses of emphysema mice. This 
result implicates the clinical usefulness of 
respiratory quinolone antibiotics against 
respiratory infection by S. pneumoniae in 
patients with COPD. 
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MATERIAL AND METHODS 
 
Animals 
Specific pathogen-free male ICR mice, 
8 weeks of age, were purchased from Japan 
Clea Co. (Tokyo, Japan). All experiments 
using mice in this study were approved by 
the institutional animal care and use com-
mittee. 
 
Preparation of Streptococcus pneumoniae 
S. pneumoniae serotype 3 (from Otsuka 
Pharmaceutical Co. Ltd., Tokushima, Ja-
pan) is penicillin-sensitive. The minimal 
inhibitory concentrations (MIC) of penicil-
lin G and GPFX against the organism were 
≤0.06 µg/ml and ≤ 0.20 µg/ml, respectively. 
S. pneumoniae were incubated at 37 °C in 
tryptic soy broth (DIFCO, Detroit, MI) with 
10 % fetal bovine serum (Takashima et al., 
1996; Tateda et al., 1996). 
 
An emphysematous model 
To produce pulmonary emphysema, 
mice were anesthetized with an intraperito-
neal injection of thiopental sodium 
(150 mg/kg body weight), and the trachea 
was intubated with a 22 gauge canula. Por-
cine pancreatic elastase (Calbiochem-Nova-
biochem Co., USA) in phosphate-buffered 
salt solution (PBS) was intratracheally ad-
ministered via a canula in doses of 12 units/ 
50 µl (Inoue et al., 2003; Karlinsky and 
Snider, 1978).  
 
Streptococcal infection 
Three weeks after elastase treatment, 
suspensions containing 107 cfu of S. pneu-
moniae/100 µl broth were intratracheally 
administered to mice under conditions of 
intraperitoneal anesthesia. 
 
Antibiotic therapy 
From 24 hrs after infection, emphyse-
matous mice were treated with antibiotic. 
Fifty mg/kg body weight of Grepafloxacin 
(GPFX) (a fluoroquinolone antibiotic, from 
Otsuka Pharmaceutical Co. Ltd., Tokushima, 
Japan) were dissolved in water, and admin-
istered orally every day for 5 days. Same 
volume of water was administered to em-
physematous mice without antibiotic ther-
apy every day. 
 
Preparation of serum 
Seventy-two hours after bacterial inocu-
lation, whole blood was obtained by direct 
puncture of the right ventricular cavity in 
mice, which had been deeply anesthetized 
with excess intraperitoneal thiopental so-
dium (450 mg/kg body weight). Individual 
sera were separated from the clotted blood 
by centrifugation, and stored at –80 °C until 
the assays were performed. 
 
Biochemical analysis of serum 
Serum levels of TNF-α, CXCL1, and 
CXCL2 were measured by an enzyme-
linked immunosorbent assay (ELISA), 
(Quantikine; R&D Systems, Minneapolis, 
MN), since these cytokines are known to 
play roles as key molecules in inflammatory 
responses in bacterial infections (Takashima 
et al., 1997; Benton et al., 1998; Standiford 
et al., 1999). 
 
Histological analysis 
For morphological examinations, both 
lungs were inflated under constant positive 
pressure (25 cm water pressure) of 10 % 
buffered formaldehyde and were then per-
fuse-fixed. The fixed lungs were embedded 
in paraffin, stained with hematoxylin and 
eosin, and examined using a microscope 
(BX50F4, Olympus, Tokyo) (Saito et al., 
2000).  
 
Statistical analysis 
All values are expressed as means ± 
standard deviation of the mean (S.D.). The 
differences between the groups were further 
compared using Mann-Whitney’s U test 
with an adjustment of the p values 
(p < 0.05). A p value of p < 0.05 was con-
sidered statistically significant. 
  
RESULTS 
Survival after infection 
Figure 1 shows the survival curves ob-
tained from 2 groups of mice with 
107 cfu/mouse of S. pneumoniae inoculation. 
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Mice with emphysema became emaciated 
and died within several days after infection. 
In sharp contrast, all emphysematous mice 
treated with GPFX were survived through-
out the observation period.  
 
Histological changes after infection  
Representative microscopic findings of 
the lungs in the emphysematous mice with 
or without antibiotic therapy 72 hrs after 
infection are shown in Figure 2. In the em-
physematous mice without therapy, poly-
morphonuclear leukocyte accumulation, 
alveolar wall thickening with eosinophilic 
materials and capillary congestion with red 
blood cells were observed (Figure 2a). 
There are no inflammatory changes in al-
veolar wall or capillary in the emphysema-
tous mice with antibiotic therapy (Figure 
2b). 
 
Systemic inflammatory changes 
Serum TNF-α, CXCL1, and CXCL2 
levels are summarized in Figure 3. Seventy-
two hours after infection, serum cytokine 
levels were significantly higher in emphy-
sematous mice without therapy than those 
with antibiotic therapy. 
 
 
 
Figure 2: Histological findings of the lung tissue sections. 
Representative images of lung tissue sections are shown (Hematoxylin and eosin stain ×100). 
a: Emphysematous mice without antibiotic therapy. Polymorphonuclear leukocyte accumulation, alveo-
lar wall thickening with eosinophilic materials and capillary congestion with red blood cells were evi-
dent. 
b: Emphysematous mice with antibiotic therapy. Significant improvements of these inflammatory 
changes were observed. 
Figure 1: Survival rate in emphyse-
matous mice with or without antibi-
otic therapy.  
 
Emphysematous mice without antibi-
otic therapy died after challenged 
107 cfu/mouse of S. pneumoniae. 
Emphysematous mice with antibiotic 
therapy did not die after infection. 
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Figure 3: Serum levels of TNF-α (a), CXCL1 (b), and CXCL2 (c) from emphysematous mice with or 
without antibiotic therapy.  
Seventy-two hrs after infection, each cytokine level in emphysematous mice with antibiotic therapy 
were significantly less than those in emphysematous mice without therapy. 
A: Emphysematous mice without antibiotic therapy; B: Emphysematous mice with antibiotic therapy. 
* p < 0.05 compared with emphysematous mice without therapy.  
 
 
DISCUSSION 
 
In the present study, we investigated the 
usefulness of early intervention using 
fluoroquinolone against streptococcal 
pneumonia in elastase-induced emphysema-
tous mice. All emphysematous mice were 
survived by antibiotic therapy after inocula-
tion of lethal dose bacteria, and have less 
pathological findings regarding to the lung 
inflammations compared to the mice with-
out antibiotic treatment, suggesting that 
early treatment by GPFX prevented the 
mice from development of pneumonia after 
bacterial infection. Systemic responses such 
as serum levels of TNF-α, CXCL1, and 
CXCL2 in emphysematous mice with anti-
biotic therapy were significantly lower than 
those without therapy. 
In our previous report, we showed that 
immediate inflammatory responses in the 
lungs 6 hours after bacterial inoculation 
were significantly enhanced (Tokairin et al., 
2008), and then subsequent inflammatory 
responses in the lungs 24 hours after inocu-
lation were significantly less in mice with 
emphysema. In contrast, systemic responses 
in emphysematous mice were significantly 
elevated compared to those in control mice 
72 hours after inoculation. Mice with pul-
monary emphysema died with bacteremia 
that is caused by the destruction of the lung-
blood barrier (Inoue et al., 2003). 
In patients with COPD, respiratory in-
fections easily deteriorate their general 
condition compared with healthy people. It 
is reported that COPD patients have not 
only frequent respiratory infections but also 
subsequent bacteremia (Bouza et al., 2005; 
Lodise et al., 2007). Thus, the lung-blood 
barrier in COPD patients is suggested to be 
also impaired as this experimental model. 
Our present data demonstrated that antibi-
otic therapy prevents emphysematous mice 
with pneumonia from death by severe sys-
temic infections. 
Acute exacerbation of patients with 
COPD is associated with decreased lung 
function and increased morbidity and mor-
tality. The majority of acute exacerbations 
of COPD are induced by respiratory patho-
gens including bacteria, and characterized 
by increased cough, sputum volume and 
purulence, dyspnea, and sometimes fever 
(Schumaker and Epstein, 2004; Soler et al., 
1998; DeAbate et al., 1999). Major bacte-
rial pathogens in acute exacerbation of 
COPD patients include Haemophils influen-
zae, S. pneumoniae, and Moraxella catar-
rhalis. In particular, S. pneumoniae is one 
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of the most frequent respiratory pathogens 
in patients with acute-exacerbated COPD 
and patients with community-acquired 
pneumonia (Schumaker and Epstein, 2004; 
Soler et al., 1998; Miravitlles et al., 1999). 
Importantly, S. pneumoniae rapidly induce 
very severe pneumonia even in healthy 
people. Thus, the management against S. 
pneumoniae infection is really important in 
patients with COPD. Although a vaccina-
tion for S. pneumoniae is available in clinic, 
many COPD patient is still dying due to the 
respiratory infection of this pathogen. 
Therefore, it is easily supposed that early 
intervention with antibiotic therapies 
against respiratory streptococcal infection 
prevent patient with COPD from lethal ill-
ness. 
GPFX is a broad-spectrum fluoroqui-
nolone with superior activity against gram-
positive bacteria such as S. pneumoniae 
compared with older quinolones. We ad-
ministered single oral dose of 50 mg/kg of 
GPFX to mice, which expected to reach as 
well dose of blood concentration as human 
which administered ordinary dosage (Cook 
et al., 1995; Wakebe et al., 1994). Although 
we performed this study when GPFX has 
been available, it is no more accessible in 
the clinic due to the severe adverse effect. 
However, other fluoroquinolones that are 
classified into the respiratory quinolone are 
expected to have similar effects on strepto-
coccal infection in COPD patients.  
In conclusion, we demonstrated an ani-
mal model of bacterial infection in mouse 
with pulmonary emphysema. Antibiotic 
treatment prevented emphysematous mice 
from severe systemic inflammation and 
death. We speculate the importance of early 
antibiotic therapy against streptococcal res-
piratory infection in COPD patients. 
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